AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03361969
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets
Trial: NCT00856869
Drug: NRL972
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
Trial: NCT01880086
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill that will have appearance identical to the treatment pill but will not contain active medication.
Trial: NCT01512446
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 pill per week
Trial: NCT03403348
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo to JNJ-64417184 in Parts 1, 2A, 2B, 3, 4, 5 and 6.
Trial: NCT01685138
Drug: LDK378
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDK378/Ceritinib was supplied as 150 mg hard gelatin capsules and administered orally
Trial: NCT02168530
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo administered daily orally
Trial: NCT01961895
Drug: Intravenous patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01155752
Drug: Pulmozyme single use ampule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: • Each Pulmozyme single use ampule delivers 2.5 mL (2.5 mg) of the sterile solution to the nebulizer bowl. The aqueous solution contains 1.0 mg/mL dornase alfa, 0.15 mg/mL calcium chloride dihydrate, and 8.77 mg/mL sodium chloride.
Trial: NCT01155752
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identical placebo
Trial: NCT00774553
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose titration of oral suspension to a tolerable dose given twice daily for 10 days.
Trial: NCT04231877
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04231877
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02768454
Drug: medical review of controlled broad-spectrum antibiotics
RxNorm normalized name: chlorhexidine gluconate Medicated Liquid Soap [Spectrum-4]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: medical review of outcome of antibiotics stewardship by pharmacists and infectious disease physicians
Trial: NCT00603577
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xaliproden matching placebo. 1 capsule per day for 6 months or until resolution of PSN (whichever comes first).
Trial: NCT00750139
Drug: NAFT-500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical cream 1 application every day up to 4 weeks weeks
Trial: NCT00750139
Drug: Naftin 1%
RxNorm normalized name: Naftin 1% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical allylamine cream applied once a day for up to 4 weeks
Trial: NCT00896181
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03571737
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen tablet
Trial: NCT01454154
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the Treatment Arm.
Trial: NCT01992653
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered at 750 milligrams per square meter (mg/m\^2) IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.
Trial: NCT01992653
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin will be administered at 50 mg/m\^2 IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.
Trial: NCT01992653
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone will be administered at 100 mg orally daily for 5 days every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles. Prednisone at 100 mg orally from Day -7 to Day -1 may be given at the discretion of the treating investigator physician.
Trial: NCT05982483
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesia as dictated by the treating emergency physician
Trial: NCT03724877
Drug: Long-acting beta2-agonist-long-acting muscarinic antagonists-inhaled corticosteroids(LABA-LAMA-ICS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (LABA-LAMA-ICS)
Trial: NCT03724877
Drug: Long-acting beta2-agonist-inhaled corticosteroids-long-acting muscarinic antagonists (LABA-LAMA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (LABA-LAMA)
Trial: NCT02591095
Drug: ABT-263
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02269228
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03919851
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of antibiotics
Trial: NCT01258062
Drug: GelVac™ nasal powder H5N1 influenza vaccine.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects will be randomized to either 30 µg of Inactivated H5N1 Influenza Vaccine Administered in GelVac™ Nasal Powder given as two doses of 15 μg in one nostril or placebo vaccine given as two doses administered in GelVac™ Nasal Powder in one nostril
Trial: NCT01258062
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects will be randomized to either 30 µg of Inactivated H5N1 Influenza Vaccine Administered in GelVac™ Nasal Powder given as two doses of 15 μg in one nostril or placebo vaccine given as two doses administered in GelVac™ Nasal Powder in one nostril
Trial: NCT00760695
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets, twice daily, for 4 weeks
Trial: NCT03971539
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo film-coated tablet matching BI 894416.
Trial: NCT03733574
Drug: LY03005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: LY03005 80 mg, oral tablets, single dose
Trial: NCT01340027
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00142727
Drug: Full opioid agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00142727
Drug: Opioid antagonist
RxNorm normalized name: OPIOID ANTAGONIST ANALGESICS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02330367
Drug: AC0010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase 1: AC0010 will be administered in escalating dosages in a period of 28-day cycles.~Phase 2: AC0010 will be administered twice-daily at RP2D.
Trial: NCT00621868
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01986127
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single intralesional administration during endoscopy
Trial: NCT02161237
Drug: Advagraf®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01702480
Drug: GSK2981710
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will be available as 10 g medium-chain triglycerides (MCT) powder sachet that will be mixed with 125 - 250 milliliters (ml) water in a shaker and taken within 15 minutes of completion of breakfast
Trial: NCT01702480
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Will be available as matching powder that will be mixed with 125 - 250 milliliters (ml) water in a shaker and taken within 15 minutes of completion of breakfast
Trial: NCT01938430
Drug: LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDV/SOF FDC tablet administered orally once daily
Trial: NCT00535782
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to tocilizumab administered by intravenous infusion every 4 weeks.
Trial: NCT00535782
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally or parenterally, 7.5-25 mg weekly.
Trial: NCT03888807
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is the Biofreeze product with all active ingredients removed. The product will be applied immediately after walking. The participant will wait 15 minutes prior to walking again.
Trial: NCT01840085
Drug: 0.03% DSC127 topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00925548
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/m\^2 (to a maximum of 600 mg) of intravenous cyclophosphamide.
Trial: NCT02680548
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01619007
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who will be treated for an acute deep vein thrombosis (DVT) with current standard of care comprising e.g. of initial treatment with low-molecular weight heparin or fondaparinux, followed by oral Vitamin-K antagonist for at least 3 months
Trial: NCT04080843
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine is a capsule in the form of 500 mg, orally, 850 mg/m2, twice daily, 2 weeks on/1 week off.
Trial: NCT01298505
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo given twice daily for 7 days
Trial: NCT04462666
Drug: Huzhang granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empty the content of one sachet into a mug, add 50ml warm water, stir until dissolved, add another 50ml hot water. Consume and complete all 100ml liquid mixture as a single dosage.
Trial: NCT04462666
Drug: Etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: take one capsule per day in the morning, at approximately 30 minutes after the meal.
Trial: NCT04462666
Drug: Huzhang granule Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empty the content of one sachet into a mug, add 50ml warm water, stir until dissolved, add another 50ml hot water. Consume and complete all 100ml liquid mixture as a single dosage.
Trial: NCT04462666
Drug: Etoricoxib Placebo
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: take one capsule per day in the morning, at approximately 30 minutes after the meal.
Trial: NCT04482543
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-silicone oil injection of 250 µg methotrexate is done at the end of surgery and is repeated at weeks 3 and 6 postoperatively.
Trial: NCT02621957
Drug: Pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single oral dose of 10 mg pravastatin on Day 1 in Period 1 and Day 7 in Period 2.
Trial: NCT04093115
Drug: CX1106
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of CX1106 at 740 mg/m2 as a 24-hour continuous infusion for 5 days (120 h, d1-5), 21 days per cycle, no more than 6 cycles
Trial: NCT00731692
Drug: FTY720
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod capsules at doses of 1.25 mg (prior to implementation of Amendment 5) and 0.5 mg (after Amendment 5) were administered orally once daily
Trial: NCT00731692
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules were administered orally once daily
Trial: NCT03306329
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets administered once daily
Trial: NCT01858649
Drug: 5 FU
RxNorm normalized name: i5 Functional Food Nutritional Powder for Suspension (Vanilla Delight)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, IV infusion 3 to 6 cycles 5-FU bolus 400 mg/m2, IV bolus 3 to 6 cycles 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion 3 to 6 cycles
Trial: NCT00116844
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT04561557
Drug: Cyclophosphamide and fludarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive one 3-day cycle of lymphodepletion starting 4 days prior to CT103A infusion on Day 0.~Subjects will be given IV infusion of cyclophosphamide 300 mg/m2/day on day -4, -3 and -2, and fludarabine 30 mg/m2 over 30 minutes administered immediately after cyclophosphamide.
Trial: NCT00879346
Drug: AZD8931
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160mg oral single dose (4 x 40mg tablets)
Trial: NCT02073461
Drug: CD1579 2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04180137
Drug: Pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After surgical intervention the active treatment group will receive sulodexide 250 lipasemic units (LSU) bid for 30 days.
Trial: NCT02073461
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02013310
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05121714
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is a 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 substrate (caffeine)
Trial: NCT04023071
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Conditioning agent
Trial: NCT04726657
Drug: Premixed Human Isophane Insulin Suspension + Human Insulin Injection
RxNorm normalized name: insulin isophane, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: premixed human insulin
Trial: NCT02387606
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo once daily.
Trial: NCT00701259
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01767688
Drug: MK-3102
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 25 mg of MK-3102 (1 x 25 mg capsule) administered orally on Day 1.
Trial: NCT00766675
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen oral tablet will be administered at a dose of 325 milligram as, once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.
Trial: NCT01048892
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04021017
Drug: Estradiol Hemihydrate Transdermal System
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants who have had their first period or have a bone age greater than or equal to 14 years will receive PrClimara® 25 (estradiol hemihydrate transdermal system - 25 mcg/day) as a weekly patch, for 24 months. Participants who have not yet had their first period and have a bone age below 14 years will receive an increasing dose of estrogen. These participants will be initiated on graduated dose of transdermal 17-β estradiol patches: 3.1 mcg/day (1/8 patch) for first six-months, 6.2 mcg/day (1/4 patch) for second six-months, 12.5 mcg/day (1/2 patch) for third six-months and 25 mcg/day (full patch) for final six-months.
Trial: NCT01098500
Drug: Tyrosine kinase inhibitors
RxNorm normalized name: BCR-ABL tyrosine kinase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib, erlotinib, gefitinib, dasatinib, imatinib, nilotinib (analyzed as a class of drugs, not by individual drug)
Trial: NCT03452488
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules
Trial: NCT02044848
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01127880
Drug: Ancef or Clindamycin
RxNorm normalized name: clindamycin Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 gm of Ancef or 300 mg Clindamycin for those who are penicillin allergic
Trial: NCT01127880
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: .9% Normal Saline as a placebo
Trial: NCT03523312
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral capecitabine at 825 mg/m2 BID on the days of RT. 5 Fluorouracil (5FU) at 250mg/m2/day, 7 days per week by a continuous IV infusion via an outpatient infusion pump) may be used instead at the discretion of the treating physician.
Trial: NCT02198495
Drug: Supplementation of ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02068157
Drug: Photodynamic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo image-guided I-PDT
Trial: NCT02198495
Drug: Supplementation of iron sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04079413
Drug: GP40071
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP40071, 100 per milliliters (U/mL) (dose range of 1 unit to 80 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake.
Trial: NCT04079413
Drug: NovoRapid® Penfill®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NovoRapid® Penfill®, 100 per milliliters (U/mL) (dose range of 1 unit to 80 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake.
Trial: NCT03805984
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered ID on Day 0 and Week 4.
Trial: NCT01216956
Drug: Extended-release nicotinic acid versus placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voluntary men with mixed dyslipidemia and abdominal obesity will receive extended release nicotinic acid. The dose of niaspan will be up-titrated for 3 weeks starting at 500 mg/d in order to reach 2g/d at start of week 4 dose which will be continued until the end of week 8. After a wash-out period of 3 weeks, they will receive placebo for 8 weeks. According to their randomization arm, subjects will receive either in first place placebo followed by extended release nicotinic acid or the opposite.
Trial: NCT00514943
Drug: BIBW 2992
FDA approved: no
EMA approved: no
PMDA approved: no
Description: experimental drug taken once daily orally
Trial: NCT02196688
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
Trial: NCT02062359
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: On days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
Trial: NCT00002599
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002599
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00644501
Drug: DiaPep277
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0mg dose, injected subcutaneously at baseline and every 3 months thereafter (at 0, 3, 6, 9, 12, 15, 18, 21 months)for a total of 8 administrations.
Trial: NCT00444808
Drug: Intranasal calcitonin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00063089
Drug: S. aureus Immune Globulin Intravenous (Human) 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00314548
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nebulize for 30 mins
Trial: NCT01583166
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1:200,000 epinephrine
Trial: NCT03106259
Drug: FURESTEM-RA Inj.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-interventional observational study
Trial: NCT00239512
Drug: Indomethacin and Ibuprofen
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01219764
Drug: Rabeprazole, metronidazole, Clarithromycin, Amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose arm:Rabeprazole (20mg), metronidazole (500mg), Clarithromycin (500mg) and Amoxicillin (1000mg) twice daily for a period of 7 days.~Half dose arm: Rabeprazole (10mg), metronidazole (250mg), Clarithromycin (250mg) and Amoxicillin (500mg) twice daily for a period of 7 days.
Trial: NCT01514838
Drug: ASP1941
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01514838
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, used only during placebo run-in period
Trial: NCT04028349
Drug: Ad26.ZEBOV/MVA-BN-Filo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candidate Ebola Vaccine